Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 2/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13312546 | 0.92 | PTGER2 (0.48) | PTGER2FFAR1FFAR4LMNAMAPT | |
| SCHEMBL13312549 | 0.91 | TUBB4A (0.48) | PTGER2FFAR1FFAR4RXRARXRB | |
| SCHEMBL13312556 | 0.90 | PTGER2 (0.48) | PTGER2FFAR1FFAR4LMNARXRA | |
| SCHEMBL13312575 | 0.89 | RXRA (0.47) | PTGER2FFAR1FFAR4LMNAMAPT | |
| SCHEMBL13312547 | 0.89 | PTGER2 (0.44) | PTGER2FFAR1FFAR4MAPTRXRA | |
| SCHEMBL13312548 | 0.89 | FFAR1 (0.47) | PTGER2FFAR1FFAR4RXRARXRB | |
| SCHEMBL13312551 | 0.88 | PTGER2 (0.47) | PTGER2FFAR1FFAR4LMNAMAPT | |
| SCHEMBL13312552 | 0.88 | PTGER2 (0.49) | PTGER2FFAR1FFAR4RXRARXRB | |
| SCHEMBL13312574 | 0.88 | PKM (0.47) | PTGER2FFAR1FFAR4LMNAMAPT | |
| SCHEMBL13312550 | 0.87 | RORC (0.46) | PTGER2FFAR1FFAR4RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | GPR119, GPR65, HCAR1 | PTGER2 3346/4885PTGER3 2442/4885FFAR1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.